fda compounding semaglutide crackdown news today 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these Report: FDA must enforce rules

Any company currently marketing compounded GLP-1 products should conduct an immediate review of all advertising and promotional materials (including website content, social media, and direct-to-consumer communications) to ensure that no claims imply FDA approval, equivalency with branded products, or clinical validation that does not exist

Obesity and adipose tissue research Type 2 diabetes and insulin resistance Knee osteoarthritis Obstructive sleep apnea Non-alcoholic steatohepatitis (NASH) Key Findings from the Literature 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents 1 Independent third-party lab reports for this peptide

It physically damages the peptide molecules

Results from additional trials are expected throughout 2026

Verification Checkpoint 3 - Manufacturer Integration Verification Platforms claiming direct manufacturer relationships should provide verifiable information about their distribution partnerships